These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 32149541)

  • 1. Treatment patterns and medical cost of systemic lupus erythematosus patients in Japan: a retrospective claims database study.
    Miyazaki C; Sruamsiri R; Mahlich J; Jung W
    J Med Econ; 2020 Jul; 23(7):786-799. PubMed ID: 32149541
    [No Abstract]   [Full Text] [Related]  

  • 2. Disease severity and economic burden in Japanese patients with systemic lupus erythematosus: A retrospective, observational study.
    Tanaka Y; Mizukami A; Kobayashi A; Ito C; Matsuki T
    Int J Rheum Dis; 2018 Aug; 21(8):1609-1618. PubMed ID: 30146745
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economic outcomes in patients diagnosed with systemic lupus erythematosus with versus without nephritis: results from an analysis of data from a US claims database.
    Pelletier EM; Ogale S; Yu E; Brunetta P; Garg J
    Clin Ther; 2009 Nov; 31(11):2653-64. PubMed ID: 20110008
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Healthcare utilization and cost of systemic lupus erythematosus in a US managed care health plan.
    Garris C; Jhingran P; Bass D; Engel-Nitz NM; Riedel A; Dennis G
    J Med Econ; 2013; 16(5):667-77. PubMed ID: 23425294
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of early versus late systemic lupus erythematosus diagnosis on clinical and economic outcomes.
    Oglesby A; Korves C; Laliberté F; Dennis G; Rao S; Suthoff ED; Wei R; Duh MS
    Appl Health Econ Health Policy; 2014 Apr; 12(2):179-90. PubMed ID: 24573911
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The economic burden of systemic lupus erythematosus in commercially- and medicaid-insured populations in the United States.
    Clarke AE; Yazdany J; Kabadi SM; Durden E; Winer I; Griffing K; Costenbader KH
    Semin Arthritis Rheum; 2020 Aug; 50(4):759-768. PubMed ID: 32531505
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Healthcare resource utilization and costs associated with long-term corticosteroid exposure in patients with systemic lupus erythematosus.
    Kabadi S; Yeaw J; Bacani AK; Tafesse E; Bos K; Karkare S; DeKoven M; Vina ER
    Lupus; 2018 Oct; 27(11):1799-1809. PubMed ID: 30068254
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-world medication use and economic outcomes in incident systemic lupus erythematosus patients in the United States.
    Kariburyo F; Xie L; Sah J; Li N; Lofland JH
    J Med Econ; 2020 Jan; 23(1):1-9. PubMed ID: 31589081
    [No Abstract]   [Full Text] [Related]  

  • 9. A Retrospective Administrative Claims Database Evaluation of the Utilization of Belimumab in US Managed Care Settings.
    Ke X; Eisenberg Lawrence DF; Oglesby A; Patel J; Kan H; Boggs R
    Clin Ther; 2015 Dec; 37(12):2852-63. PubMed ID: 26547483
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Healthcare Costs and Utilization for Patients With Systemic Lupus Erythematosus in China: A National Claims Database Study.
    He X; Lloyd E; Cooper S; Li L; Chauhan D; Juliao P; Quasny H; Bao C
    Value Health Reg Issues; 2023 Sep; 37():88-96. PubMed ID: 37379801
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Retrospective Analysis of Disease Severity, Health Care Resource Utilization, and Costs Among Patients Initiating Belimumab for the Treatment of Systemic Lupus Erythematosus.
    Lokhandwala T; Coutinho AD; Bell CF
    Clin Ther; 2021 Aug; 43(8):1320-1335. PubMed ID: 34243966
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Healthcare resource utilization and costs in patients with a newly confirmed diagnosis of lupus nephritis in the United States over a 5-year follow-up period.
    Bell CF; Wu B; Huang SP; Rubin B; Averell CM; Chastek B; Hulbert EM
    BMC Health Serv Res; 2024 May; 24(1):691. PubMed ID: 38822336
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Demographics, treatment patterns, and healthcare utilization and cost of repository corticotropin injection in patients with systemic lupus erythematosus or rheumatoid arthritis.
    Wu B; Deshpande G; Gu T; Popelar B; Philbin M; Wan GJ
    J Med Econ; 2017 Nov; 20(11):1170-1177. PubMed ID: 28760047
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical and economic characterization of mild, moderate, and severe systemic lupus erythematosus: Real-world observation across payer channels in the United States.
    Wu SS; Perry A; Tkacz J; Bryant G
    J Manag Care Spec Pharm; 2023 Sep; 29(9):1010-1020. PubMed ID: 37610115
    [No Abstract]   [Full Text] [Related]  

  • 15. Healthcare utilization and comorbidity burden among children and young adults in the United States with systemic lupus erythematosus or inflammatory bowel disease.
    Karve S; Candrilli S; Kappelman MD; Tolleson-Rinehart S; Tennis P; Andrews E
    J Pediatr; 2012 Oct; 161(4):662-670.e2. PubMed ID: 22578787
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hospital Healthcare Resource Utilization and Associated Hospital Costs of Patients With Lupus Nephritis in China: A National Administrative Claim Database Study.
    He X; Zhu X; Tang Z; Gairy K; Juliao P; Wu Z; Han S
    Value Health Reg Issues; 2024 Sep; 43():101001. PubMed ID: 38850589
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-world treatment patterns, healthcare resource utilisation and costs in patients with systemic lupus erythematosus treated with belimumab: a retrospective analysis of claims data in the USA.
    Bell CF; Priest J; Stott-Miller M; Kan H; Amelio J; Song X; Limone B; Noxon V; Costenbader KH
    Lupus Sci Med; 2020; 7(1):e000357. PubMed ID: 32341790
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The cost of flares among patients with systemic lupus erythematosus with and without lupus nephritis in the United States.
    Bell CF; Huang SP; Cyhaniuk A; Averell CM
    Lupus; 2023 Feb; 32(2):301-309. PubMed ID: 36542670
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment patterns and healthcare resource utilization in palmoplantar pustulosis patients in Japan: A claims database study.
    Miyazaki C; Sruamsiri R; Mahlich J; Jung W
    PLoS One; 2020; 15(5):e0232738. PubMed ID: 32442204
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Healthcare Utilization and Costs of Systemic Lupus Erythematosus by Disease Severity in the United States.
    Murimi-Worstell IB; Lin DH; Kan H; Tierce J; Wang X; Nab H; Desta B; Alexander GC; Hammond ER
    J Rheumatol; 2021 Mar; 48(3):385-393. PubMed ID: 32611669
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.